DDIT4 and breast carcinoma: In women with breast cancer melatonin proved to be a beneficial enhancer of ATO therapeutic effect, presumably by targeting ROS/Redd1 pathways [44, 48] with impact on the p53-dependent DNA damage response and p63-mediated regulation of epithelial differentiation gene [66].